1991
DOI: 10.1002/ijc.2910490222
|View full text |Cite
|
Sign up to set email alerts
|

Synergistic anti‐tumor effects of combined IL‐1/IFN‐α/β therapy in mice injected with met astatic friend erythroleukemia cells

Abstract: Peritumoral injection of relatively low doses of either mouse interferon (IFN)-alpha/beta (10,000-20,000 units/injection) or of recombinant human interleukin-1 (IL-1) beta (125-250 ng/injection) in mice transplanted s.c. with Friend erythroleukemia cells (FLC) resulted in some inhibition of primary tumor growth, inhibition of liver and splenic metastases and increased survival time. A synergistic anti-tumor effect was observed in mice injected with both IL-1 and IFN-alpha/beta. Highly purified mouse IFN-beta a… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

0
5
0

Year Published

1993
1993
2019
2019

Publication Types

Select...
5
1

Relationship

0
6

Authors

Journals

citations
Cited by 6 publications
(5 citation statements)
references
References 21 publications
0
5
0
Order By: Relevance
“…In an attempt to determine the possible mechanisms responsible for such a powerful antitumor response, studies were performed using 3Cl-8 FLC line because of the extensive information available on the in vivo behavior of these tumor cells and their response to different therapy regimens. This highly metastatic tumor has been used widely by our group for evaluating the antitumor response to type I IFN (44)(45)(46)(47) and other cytokines, as well as to chemotherapy (32,(48)(49)(50). In particular, DBA/2 mice bearing metastatic FLC do not develop a clear antitumor response after treatment with various cytokines or chemotherapeutic agents, with the notable exception of type I IFN, which markedly inhibited tumor growth and visceral metastases (41,48).…”
Section: Resultsmentioning
confidence: 99%
“…In an attempt to determine the possible mechanisms responsible for such a powerful antitumor response, studies were performed using 3Cl-8 FLC line because of the extensive information available on the in vivo behavior of these tumor cells and their response to different therapy regimens. This highly metastatic tumor has been used widely by our group for evaluating the antitumor response to type I IFN (44)(45)(46)(47) and other cytokines, as well as to chemotherapy (32,(48)(49)(50). In particular, DBA/2 mice bearing metastatic FLC do not develop a clear antitumor response after treatment with various cytokines or chemotherapeutic agents, with the notable exception of type I IFN, which markedly inhibited tumor growth and visceral metastases (41,48).…”
Section: Resultsmentioning
confidence: 99%
“…On E14.5, pregnant females were i.v. injected with a single dose of 22,700 U [61] or 45,400 U recombinant mouse IFNβ (PBL Assay Science, NJ, USA) dissolved in 100 µl vehicle (PBS supplemented with 0.1% FCS), or an equivalent volume of vehicle as a control.…”
Section: Maternal Treatment With Interferon Beta (Ifnβ)mentioning
confidence: 99%
“…1d), we decided to use this cytokine for our subsequent experiments. Pregnant dams were injected at E14.5 with IFNβ (22,700 U) [61] or vehicle, as a control (see Materials and Methods), and the microglia of newborn offspring were examined (Fig. 3d).…”
Section: Maternal Ifnβ Signaling Downregulates Newborn's Microglial Pmentioning
confidence: 99%
“…mL -1 ) within their respective groups. Both cytokines share the ability to produce fever, lethargy, somnolence and anorexia; additive and synergistic interactions theoretically occur between them at several levels [15]. It is thus plausible that the combination of IFN-α and IL-1 somehow contributes to the systemic signs of the dual PRRSV-PRCV infection.…”
Section: Dual Infections With Respiratory Virusesmentioning
confidence: 99%